Amgen says cancer treatment missed endpoint in late-stage clinical trial

Company shares fell 1.5% in premarket trading Tuesday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.